Genocea Biosciences Obtains $35,000,000 Series B Funding Round

  • Feed Type
  • Date
  • Company Name
    Genocea Biosciences
  • Mailing Address
    161 First Street Cambridge, MA 02142
  • Company Description
    Genocea was founded in 2006 based on technology from University of California at Berkeley and Harvard Medical School. Infectious diseases are the third leading cause of death each year in the United States and the world’s leading killer of children and young adults, accounting for more than 14 million deaths annually. In addition, numerous infectious diseases, while not major killers, cause chronic disability for millions and lead to tens of billions of dollars in excess healthcare costs. Many infectious diseases, such as malaria and tuberculosis (two of the top five global killers) as well as chlamydia (the most frequently reported bacterial sexually transmitted disease in the United States), are caused by pathogens that are capable of growing within human cells (intracellular pathogens). Despite the devastating health and economic impact of these diseases, and in spite of significant efforts to develop vaccines, no effective vaccines currently exist against these or a multitude of ot
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds will support Genocea as it enters clinical development for its lead program, a therapeutic vaccine for herpes simplex virus type 2 (HSV-2) infections. Genocea will also use funds to advance its deep research pipeline, including prophylactic vaccine programs addressing Chlamydia trachomatis, Streptococcus pneumoniae, HSV-2 and Plasmodium falciparum (malaria).
  • M&A Terms
  • Venture Investor
    Johnson & Johnson Development Corporation
  • Venture Investor
    Skyline Ventures
  • Venture Investor
    Polaris Venture Partners
  • Venture Investor
    SR One
  • Venture Investor
    Lux Capital
  • Venture Investor
    Cycad Group
  • Venture Investor
    Auriga Partners
  • Venture Investor
    Morningside Group

Trending on Xconomy